Redwood Grove Capital LLC acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,525,300 shares of the company's stock, valued at approximately $37,538,000. Elanco Animal Health accounts for approximately 9.5% of Redwood Grove Capital LLC's holdings, making the stock its largest holding. Redwood Grove Capital LLC owned 0.31% of Elanco Animal Health as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. NewEdge Advisors LLC lifted its holdings in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after acquiring an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Elanco Animal Health in the 2nd quarter valued at $38,000. Root Financial Partners LLC raised its position in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after purchasing an additional 592 shares during the period. Uniplan Investment Counsel Inc. purchased a new position in Elanco Animal Health in the fourth quarter valued at about $41,000. Finally, Torren Management LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter worth about $46,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.
Elanco Animal Health Stock Up 2.8%
Shares of Elanco Animal Health stock opened at $25.11 on Wednesday. The stock has a market capitalization of $12.55 billion, a price-to-earnings ratio of -61.25, a PEG ratio of 1.46 and a beta of 1.67. Elanco Animal Health Incorporated has a twelve month low of $17.11 and a twelve month high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The business's 50 day simple moving average is $24.58 and its 200-day simple moving average is $24.01.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.
Insider Activity
In other news, Director Lawrence Erik Kurzius bought 40,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, with a total value of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares in the company, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Herendeen bought 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average price of $23.68 per share, with a total value of $236,800.00. Following the completion of the acquisition, the director directly owned 111,687 shares of the company's stock, valued at $2,644,748.16. This represents a 9.83% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 63,198 shares of company stock valued at $1,473,109 over the last 90 days. Corporate insiders own 1.14% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on ELAN. TD Cowen boosted their price target on Elanco Animal Health from $31.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, June 18th. Weiss Ratings downgraded shares of Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday, August 20th. Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 22nd. UBS Group lifted their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $29.09.
Read Our Latest Report on ELAN
Elanco Animal Health Profile
(
Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Elanco Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.
While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
